2024
Optimizing public-private partnerships to support clinical cancer research
Herbst R, Blumenthal G, Khleif S, Lippman S, Meropol N, Rosati K, Shulman L, Smith H, Wang M, Winn R, Schilsky R. Optimizing public-private partnerships to support clinical cancer research. Journal Of The National Cancer Institute 2024, djae279. PMID: 39666955, DOI: 10.1093/jnci/djae279.Peer-Reviewed Original ResearchClinical cancer researchNational Cancer Policy ForumPublic-private partnershipEquitable care deliveryCancer researchCare deliveryEfficient drug developmentImplementation of public-private partnershipPromote collaborationTherapeutic innovationsClinical applicationPartnershipPolicy forumsDrug developmentNonprofit organizations
2022
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.
Hayes D, Herbst R, Myles J, Topalian S, Yohe S, Aronson N, Bellizzi A, Basu Roy U, Bradshaw G, Edwards R, El-Gabry E, Elvin J, Gajewski T, McShane L, Oberley M, Philip R, Rimm D, Rosenbaum J, Rubin E, Schlager L, Sherwood S, Stewart M, Taube J, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precision Oncology 2022, 6: e2200454. PMID: 36446042, PMCID: PMC10530621, DOI: 10.1200/po.22.00454.Peer-Reviewed Original ResearchConceptsICI therapyImmune checkpoint inhibition therapyDeath ligand 1 (PD-L1) expressionMultiple predictive biomarkersTumor biomarker testsCheckpoint inhibition therapyLigand 1 expressionDeath ligand 1Field of oncologyICI benefitPredictive factorsPredictive biomarkersInhibition therapyNeoantigen expressionBiomarker testsHealth insurance organizationsUS FoodDrug AdministrationAmerican PathologistsMedicaid ServicesTherapyBiomarker developmentNational InstituteLigand 1Clinical application